Retatrutide Dose Calculator
— Free Online Tool

Calculate exact injection volumes, concentrations, and doses per vial for Retatrutide protocols.

⚠️ Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any peptide or medication protocol.

⚡ Retatrutide Dose Calculator

Concentration—
Volume Per Injection—
Insulin Syringe Units—
Doses Per Vial—

📱 Track Every Dose with DoseIQ

The #1 peptide tracking app for iPhone. Calculate doses, log injections, set reminders, and track your progress.

⬇️ Download Free on App Store

What is Retatrutide?

Retatrutide is a next-generation triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — the most powerful weight loss compound in clinical development. Phase 2 trials by Eli Lilly demonstrated up to 24% body weight reduction, exceeding both semaglutide (~15%) and tirzepatide (~22%). Adding glucagon receptor activation further increases energy expenditure and fatty acid oxidation. Currently in Phase 3 trials; FDA approval expected 2026–2027. Compounded research versions available.

Retatrutide Quick Reference

ParameterDetails
CategoryGLP-1 / Weight Loss
Common Dose4,000–12,000 mcg
FrequencyOnce weekly
Half-Life~6 days
Injection SitesSubcutaneous — abdomen, thigh, or upper arm

Benefits of Retatrutide

Common Dosing Protocols

Research Starting Dose: 4 mg (4,000 mcg) weekly.
Phase 2 Efficacy Dose: 8 mg weekly — strongest results in trials.
Maximum Research Dose: 12 mg weekly.

Reconstitution Reference Table

Vial SizeBAC WaterConcentrationLow Dose VolumeHigh Dose Volume
10 mg2 mL5,000 mcg/mL0.80 mL1.60 mL
10 mg4 mL2,500 mcg/mL1.60 mL3.20 mL

How to Reconstitute Retatrutide

1
Add 2 mL BAC water to 10 mg vial = 5,000 mcg/mL
2
4 mg = 0.80 mL | 8 mg = 1.60 mL
3
Refrigerate; use within 28 days

Frequently Asked Questions

Q: Retatrutide research starting dose?
A: 4 mg weekly. Phase 2 trials used 4 mg, 8 mg, and 12 mg doses weekly.
Q: Is retatrutide FDA-approved?
A: Not as of 2026. In Phase 3 trials by Eli Lilly. Only compounded research peptides currently available.
Q: Retatrutide vs tirzepatide?
A: Adds glucagon receptor agonism resulting in ~24% weight loss vs tirzepatide's ~22% in Phase 2 data.

Related Calculators

Tirzepatide Calculator →Semaglutide Calculator →Ozempic (Semaglutide) Calculator →Wegovy (Semaglutide) Calculator →

📱 Track Every Dose with DoseIQ

The #1 peptide tracking app for iPhone. Calculate doses, log injections, set reminders, and track your progress.

⬇️ Download Free on App Store